Report Store Get Proposal

Home Blog Notizia 40

Notizia - Recent Pharma, Healthcare and Biotech Happenings

recent-pharma-news-updates-for-artios-scholar-rock-novavax-volastra

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M

Artios Pharma announces collaboration with Novartis to tap next-generation DDR cancer therapies Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploiting synthetic lethality to create a broad pipeline of precision medicines for cancer treatment, announced a global research collaboration with Novartis to discover and validate next-generation DDR targets to improve Novartis’ Radioligand Therapies (RLT). Artios and Novartis will execute target discovery and confirmation under the three-year deal, and Novartis will choose three exclusive DDR targets and receive global rights on these targets to be utilised with its RLT’s. Under the terms of th...

Explore More...

Default Blog Image

GeneDx secures $92M funding; BioTech Innovations partners with Novartis for R&D collaboration

Therapeutics

Business Cocktail

astellas

Commercial Outcomes – Novartis

cancer

Key Clinical Outcomes- 30/07/2018

aristada

Neuroscience Highlights – 17/07/2018

MERCK ONCOLOGY

Oncology Highlights – 30/07/2018

transthyretin amyloidosis

Notizia

transthyretin amyloidosis

Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates

transthyretin amyloidosis

Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation

Notizia

Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating

Entasis

Business Cocktail

transthyretin amyloidosis

Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod

Default Blog Image

Horizon Discovery declines Abcam’s USD 367 million takeover bid

transthyretin amyloidosis

Notizia

transthyretin amyloidosis

Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients

Default Blog Image

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly